A multidisciplinary approach to squamous cell carcinomas of the head and neck: An update

Current Opinion in Oncology

Volumn 20, Issue 3, 2008, Pages 249-255

  Bernier, Jacques ^a  

^a Genolier Swiss Medical Network SA   (Switzerland)

Author keywords

Cetuximab; Chemoradiotherapy; Epidermal growth factor receptor; Locally advanced squamous cell carcinoma of the head and neck; Radiotherapy

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; IMMUNOGLOBULIN G1; MITOMYCIN C; MONOCLONAL ANTIBODY;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; DISEASE FREE SURVIVAL; DYSPHAGIA; HEAD AND NECK CARCINOMA; HUMAN; MUCOSA INFLAMMATION; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DERMATITIS; RADIATION DOSE FRACTIONATION; REVIEW; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STOMATITIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; DOSE FRACTIONATION; HEAD AND NECK NEOPLASMS; HUMANS; NEOADJUVANT THERAPY; QUALITY OF LIFE; RADIOTHERAPY, ADJUVANT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS;

EID: 41949104287     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3282faa0b1     Document Type: Review

References (39)

1. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000; 48:7-16.
2. Pignon JP, Le Maître A, Bourhis J. Meta-analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 2007; 69:S112-114. This updated meta-analysis confirmed a survival benefit of CRT over radiotherapy alone but showed no survival advantage for induction chemotherapy.
3. Budach W, Hehr T, Budach V, et al. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 2006; 6:28.
4. Skladowski K, Maciejewski B, Golen M, et al. Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of phase III clinical trial. Int J Radiat Oncol Biol Phys 2006; 66:706-713.
5. Kasibhatla M, Kirkpatrick JP, Brizel DM. How much radiation is the chemotherapy worth in advanced head and neck cancer? Int J Radiat Oncol Biol Phys 2007; 68:1491-1495. In this paper, the authors calculated that the addition of chemotherapy to radiotherapy increased the biologic equivalent dose by around 10 Gy, more than could safely be achieved with radiotherapy alone.
6. Staar S, Rudat V, Stuetzer H, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy: results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 50:1161-1171.
7. Semrau R, Mueller RP, Stuetzer H, et al. Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: updated results of a randomized multicentric trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2006; 64:1308-1316.
8. Bernier J. Alteration of radiotherapy fractionation and concurrent chemotherapy: a new frontier in head and neck oncology? Nat Clin Pract Oncol 2005; 2:305-314.
9. Eisbruch A. Commentary: induction chemotherapy for head and neck cancer: hypothesis-based rather than evidence-based medicine. Oncologist 2007; 12:975-977.
10. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357:1705-1715. A US randomized, phase III trial demonstrating that the addition of docetaxel to induction therapy with cisplatin and 5-FU, prior to CRT, improves survival compared with cisplatin and 5-FU alone.
11. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357:1695-1704. A European randomized, phase III trial demonstrating that the addition of docetaxel to induction therapy with cisplatin and 5-FU improves survival compared with cisplatin and 5-FU alone.
12. Rivera F, Vega-Villegas ME, Lopez-Brea M, et al. Randomized phase II study of cisplatin and 5-FU continuous infusion (PF) versus cisplatin, UFT and vinorelbine (UFTVP) as induction chemotherapy in locally advanced squamous cell head and neck cancer (LA-SCHNC). Cancer Chemother Pharmacol 2007 [Epub ahead of print].
13. Bernier J, Bonner J, Vermorken J, et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008; 19:142-149. The first international consensus guidelines produced for the treatment of radiation dermatitis.
14. Macmillan MS, Wells M, MacBride S, et al. Randomized comparison of dry dressings versus hydrogel in management of radiation-induced moist desquamation. Int J Radiat Oncol Biol Phys 2007; 68:864-872.
15. Cummings B, Keane T, Pintilie M, et al. Five year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer. Radiother Oncol 2007; 85:7-16. Long-term follow-up of a randomized trial demonstrating that treatment with hyperfractionated radiation does not increase the incidence of late, severe toxicities compared with conventionally fractionated radiation.
16. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21:92-98.
17. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350:1945-1952.
18. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999; 91:2081-2086.
19. Wendt TG, Grabenbauer GG, Rodel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998; 16:1318-1324.
20. Argiris A, Li Y, Forastiere A. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 2004; 101:2222-2229.
21. Huguenin P, Beer KT, Allal A, et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 2004; 22:4665-4673.
22. Trotti A, Pajak TF, Gwede CK, et al. TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol 2007; 8:613-624. Proposal for a new method for recording adverse events to better appreciate the toxicity burden of radiotherapy/CRT. The authors suggest that there is considerable under reporting of adverse events and that this is particularly marked with more intense treatment regimens.
23. Bentzen SM, Trotti A. Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol 2007; 25:4096-4103.
24. de Graeff A, de Leeuw JR, Ros WJ, et al. Sociodemographic factors and quality of life as prognostic indicators in head and neck cancer. Eur J Cancer 2001; 37:332-339.
25. Movsas B, Scott C, Watkins-Bruner D. Pretreatment factors significantly influence quality of life in cancer patients: a Radiation Therapy Oncology Group (RTOG) analysis. Int J Radiat Oncol Biol Phys 2006; 65:830-835.
26. Siddiqui F, Pajak TF, Watkins-Bruner D, et al. Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: a Radiation Therapy Oncology Group analysis. Int J Radiat Oncol Biol Phys 2008; 70:353-360. In what the authors consider to be the largest analysis of its kind, analysis of data from two randomized RTOG trials showed health-related QoL to be a significant and independent predictor of locoregional control in locally advanced head and neck cancer.
27. Coyne JC, Pajak TF, Harris J, et al. Emotional well being does not predict survival in head and neck cancer patients: a radiation therapy oncology group study. Cancer 2007; 110:2568-2575. Analysis of data from two randomized RTOG trials demonstrated that emotional functioning was not an independent predictor of survival in patients with cancer.
28. Mowry SE, Ho A, Lotempio MM, et al. Quality of life in advanced oropharyngeal carcinoma after chemoradiation versus surgery and radiation. Laryngoscope 2006; 116:1589-1593.
29. Nguyen NP, Vos P, Karlsson U, et al. Quality of life following chemoradiation and postoperative radiation for locally advanced head and neck cancer. ORL J Otorhinolaryngol Relat Spec 2007; 69:271-276.
30. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62:7350-7356.
31. Bernier J, Schneider D. Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck? Eur J Cancer 2007; 43:35-45.
32. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
33. Budach V, Stuschke M, Budach W, et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol 2005; 23:1125-1135.
34. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004; 22:69-76.
35. Budach W, Bolke E, Homey B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 2007; 357:514-515.
36. Herchenhorn D, Dias FL, Pineda RM, et al. Phase II study of erlotinib combined with cisplatin and radiotherapy for locally advanced squamous cell carcinoma of the head and neck (SCCHN) [Abstract]. J Clin Oncol 2007; 25:6033.
37. Lord HK, Junor E, Ironside J. Cetuximab is effective, but more toxic than reported in the Bonner trial. Clin Oncol (R Coll Radiol) 2008; 20:96.
38. Curran D, Giralt J, Harari PM, et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 2007; 25:2191-2197. This QoL analysis of the randomized, phase III study of radiotherapy and cetuximab versus radiotherapy alone demonstrates that the addition of cetuximab has no negative impact on patients' QoL. Of note, the rash associated with EGFR inhibitors did not have a negative effect on social functioning.
39. Brown B, Diamantopoulos A, Bernier J, et al. An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland and the United Kingdom. Value Health 2007 [Epub ahead of print].